Literature DB >> 24564400

Conditional overexpression of liver receptor homolog-1 in female mouse mammary epithelium results in altered mammary morphogenesis via the induction of TGF-β.

Kyren A Lazarus1, Kristy A Brown, Morag J Young, Zhe Zhao, Rhiannon S Coulson, Ashwini L Chand, Colin D Clyne.   

Abstract

Liver receptor homolog-1 (LRH-1) is an orphan nuclear receptor that belongs to the NR5A subgroup of nuclear receptors. LRH-1 induces key genes to regulate metabolic process, ovarian function, cancer cell proliferation, and steroidogenesis. In the breast, LRH-1 modulates and synergizes with endogenous estrogen signaling to promote breast cancer cell proliferation. We used small interfering RNA knockdown strategies to deplete LRH-1 in breast cancer cells and followed with microarray analysis to identify LRH-1-dependent mechanisms. We identified key genes involved in TGF-β signaling to be highly responsive to LRH-1 knockdown. This relationship was validated in 2 breast cancer cell lines overexpressing LRH-1 in vitro and in a novel transgenic mouse with targeted LRH-1 overexpression in mammary epithelial cells. Notably, TGF-β signaling was activated in LRH-1-overexpressing breast cancer cells and mouse mammary glands. Further analyses of mammary gross morphology revealed a significant reduction in mammary lateral budding after LRH-1 overexpression. These findings suggest that the altered mammary morphogenesis in LRH-1 transgenic animals is mediated via enhanced TGF-β expression. The regulation of TGF-β isoforms and SMAD2/3-mediated downstream signaling by LRH-1 also implicates a potential contribution of LRH-1 in breast cancer. Collectively, these data demonstrate that LRH-1 regulates TGF-β expression and downstream signaling in mouse mammary glands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24564400     DOI: 10.1210/en.2013-1948

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.

Authors:  Vineet K Dhiman; Michael J Bolt; Kevin P White
Journal:  Nat Rev Genet       Date:  2017-12-27       Impact factor: 53.242

Review 2.  Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation.

Authors:  Gerard A Tarulli; Geraldine Laven-Law; Reshma Shakya; Wayne D Tilley; Theresa E Hickey
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-09-21       Impact factor: 2.673

3.  Silencing LRH-1 in colon cancer cell lines impairs proliferation and alters gene expression programs.

Authors:  James R Bayrer; Sridevi Mukkamala; Elena P Sablin; Paul Webb; Robert J Fletterick
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

Review 4.  Liver receptor homolog-1 (LRH-1): a potential therapeutic target for cancer.

Authors:  Christina Nadolny; Xiaoqun Dong
Journal:  Cancer Biol Ther       Date:  2015-05-07       Impact factor: 4.742

5.  The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.

Authors:  Rhiannon Coulson; Seng H Liew; Angela A Connelly; Nicholas S Yee; Siddhartha Deb; Beena Kumar; Ana C Vargas; Sandra A O'Toole; Adam C Parslow; Ashleigh Poh; Tracy Putoczki; Riley J Morrow; Mariah Alorro; Kyren A Lazarus; Evie F W Yeap; Kelly L Walton; Craig A Harrison; Natalie J Hannan; Amee J George; Colin D Clyne; Matthias Ernst; Andrew M Allen; Ashwini L Chand
Journal:  Oncotarget       Date:  2017-03-21

6.  The V-ATPase a2 isoform controls mammary gland development through Notch and TGF-β signaling.

Authors:  Sahithi Pamarthy; Liquin Mao; Gajendra K Katara; Sara Fleetwood; Arpita Kulshreshta; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

7.  LRH1 Acts as an Oncogenic Driver in Human Osteosarcoma and Pan-Cancer.

Authors:  Yang Song; Weiwei An; Hongmei Wang; Yuanren Gao; Jihua Han; Chenguang Hao; Lin Chen; Shilong Liu; Ying Xing
Journal:  Front Cell Dev Biol       Date:  2021-03-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.